OTCMKTS:EAPH

Easton Pharmaceuticals Competitors

$0.0020
0.00 (0.00 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.00
Now: $0.00
$0.00
50-Day Range N/A
52-Week Range
$0.00
Now: $0.00
$0.02
Volume1.59 million shs
Average Volume1.94 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Easton Pharmaceuticals (OTCMKTS:EAPH) Vs. ABAHF, ACRGF, APPB, AYRSF, CANB, and CNTMF

Should you be buying EAPH stock or one of its competitors? Companies in the industry of "drug manufacturers - specialty & generic" are considered alternatives and competitors to Easton Pharmaceuticals, including Abacus Health Products (ABAHF), Acreage (ACRGF), Applied Biosciences (APPB), Ayr Strategies (AYRSF), Can B (CANB), and Cansortium (CNTMF).

Easton Pharmaceuticals (OTCMKTS:EAPH) and Abacus Health Products (OTCMKTS:ABAHF) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, valuation and profitability.

Valuation & Earnings

This table compares Easton Pharmaceuticals and Abacus Health Products' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Easton PharmaceuticalsN/AN/AN/AN/AN/A
Abacus Health ProductsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and target prices for Easton Pharmaceuticals and Abacus Health Products, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Easton Pharmaceuticals0000N/A
Abacus Health Products0000N/A

Profitability

This table compares Easton Pharmaceuticals and Abacus Health Products' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Easton PharmaceuticalsN/AN/AN/A
Abacus Health ProductsN/AN/AN/A

Acreage (OTCMKTS:ACRGF) and Easton Pharmaceuticals (OTCMKTS:EAPH) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Valuation and Earnings

This table compares Acreage and Easton Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AcreageN/AN/AN/AN/AN/A
Easton PharmaceuticalsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations and price targets for Acreage and Easton Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acreage01202.67
Easton Pharmaceuticals0000N/A

Acreage presently has a consensus target price of $8.4333, suggesting a potential upside of 204.45%. Given Acreage's higher probable upside, research analysts plainly believe Acreage is more favorable than Easton Pharmaceuticals.

Profitability

This table compares Acreage and Easton Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AcreageN/AN/AN/A
Easton PharmaceuticalsN/AN/AN/A

Summary

Acreage beats Easton Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

Applied Biosciences (OTCMKTS:APPB) and Easton Pharmaceuticals (OTCMKTS:EAPH) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability.

Profitability

This table compares Applied Biosciences and Easton Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Applied BiosciencesN/AN/AN/A
Easton PharmaceuticalsN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings for Applied Biosciences and Easton Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Applied Biosciences0000N/A
Easton Pharmaceuticals0000N/A

Valuation and Earnings

This table compares Applied Biosciences and Easton Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied BiosciencesN/AN/AN/AN/AN/A
Easton PharmaceuticalsN/AN/AN/AN/AN/A

Ayr Strategies (OTCMKTS:AYRSF) and Easton Pharmaceuticals (OTCMKTS:EAPH) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Ayr Strategies and Easton Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ayr Strategies01602.86
Easton Pharmaceuticals0000N/A

Ayr Strategies presently has a consensus target price of $34.8571, indicating a potential upside of 63.96%. Given Ayr Strategies' higher probable upside, equities analysts clearly believe Ayr Strategies is more favorable than Easton Pharmaceuticals.

Valuation and Earnings

This table compares Ayr Strategies and Easton Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ayr StrategiesN/AN/AN/AN/AN/A
Easton PharmaceuticalsN/AN/AN/AN/AN/A

Profitability

This table compares Ayr Strategies and Easton Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ayr StrategiesN/AN/AN/A
Easton PharmaceuticalsN/AN/AN/A

Summary

Ayr Strategies beats Easton Pharmaceuticals on 2 of the 2 factors compared between the two stocks.

Can B (NASDAQ:CANB) and Easton Pharmaceuticals (OTCMKTS:EAPH) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Profitability

This table compares Can B and Easton Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Can BN/AN/AN/A
Easton PharmaceuticalsN/AN/AN/A

Valuation and Earnings

This table compares Can B and Easton Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Can BN/AN/AN/AN/AN/A
Easton PharmaceuticalsN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and price targets for Can B and Easton Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Can B0000N/A
Easton Pharmaceuticals0000N/A

Cansortium (OTCMKTS:CNTMF) and Easton Pharmaceuticals (OTCMKTS:EAPH) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability.

Earnings & Valuation

This table compares Cansortium and Easton Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CansortiumN/AN/AN/AN/AN/A
Easton PharmaceuticalsN/AN/AN/AN/AN/A

Profitability

This table compares Cansortium and Easton Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CansortiumN/AN/AN/A
Easton PharmaceuticalsN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and target prices for Cansortium and Easton Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cansortium00103.00
Easton Pharmaceuticals0000N/A

Cansortium presently has a consensus target price of $1.20, suggesting a potential upside of 43.13%. Given Cansortium's higher probable upside, analysts plainly believe Cansortium is more favorable than Easton Pharmaceuticals.

Summary

Cansortium beats Easton Pharmaceuticals on 2 of the 2 factors compared between the two stocks.


Easton Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ABAHF
Abacus Health Products
0.4$4.84flat$0.00N/A0.00Gap Up
Acreage logo
ACRGF
Acreage
1.2$2.77flat$0.00N/A0.00
APPB
Applied Biosciences
0.5$0.25flat$0.00N/A0.00High Trading Volume
Gap Up
AYRSF
Ayr Strategies
1.4$21.26flat$0.00N/A0.00
Can B logo
CANB
Can B
0.4$0.56flat$0.00N/A0.00Gap Up
Cansortium logo
CNTMF
Cansortium
1.1$0.84flat$0.00N/A0.00
Charlotte's Web logo
CWBHF
Charlotte's Web
1.3$4.30flat$0.00N/A0.00
Choom logo
CHOOF
Choom
0.5$0.10flat$0.00N/A0.00Gap Up
CPHRF
Cipher Pharmaceuticals
1.2$1.08flat$0.00N/A0.00
CLS Holdings USA logo
CLSH
CLS Holdings USA
0.7$0.22flat$0.00N/A0.00Gap Down
Cosmos logo
COSM
Cosmos
0.5$5.70flat$0.00N/A0.00Gap Up
Cresco Labs logo
CRLBF
Cresco Labs
1.5$12.48flat$0.00N/A0.00
Curaleaf logo
CURLF
Curaleaf
1.6$14.42flat$0.00N/A0.00
HMDEF
DionyMed Brands
0.5N/AN/A$0.00N/A0.00High Trading Volume
Elixinol Global logo
ELLXF
Elixinol Global
0.8$0.15flat$0.00N/A0.00Gap Down
EVIO
EVIO
0.6$0.00flat$0.00N/A0.00Gap Down
Flower One logo
FLOOF
Flower One
0.4$0.28flat$0.00N/A0.00Gap Up
Golden Leaf logo
GLDFF
Golden Leaf
0.5$0.05flat$0.00N/A0.00Gap Down
Green Growth Brands logo
GGBXF
Green Growth Brands
0.4$0.01flat$0.00N/A0.00Gap Down
Green Thumb Industries logo
GTBIF
Green Thumb Industries
1.7$28.53flat$0.00N/A0.00Gap Up
GTEC logo
GGTTF
GTEC
0.6$0.61flat$0.00N/A0.00News Coverage
Gap Down
Harvest Health & Recreation logo
HRVSF
Harvest Health & Recreation
1.3$2.92flat$0.00N/A0.00
Hemp Naturals logo
HPMM
Hemp Naturals
0.6$0.01flat$0.00N/A0.00
Hexo logo
HYYDF
Hexo
0.6$5.30flat$0.00N/A0.00
Hikma Pharmaceuticals logo
HKMPY
Hikma Pharmaceuticals
0.4$59.68flat$0.00N/A0.00
iAnthus Capital logo
ITHUF
iAnthus Capital
0.6$0.23flat$0.00N/A0.00Gap Up
Icanic Brands logo
ICNAF
Icanic Brands
0.6$0.34flat$0.00N/A0.00
KNHBF
ICC International Cannabis
0.6N/AN/A$0.00N/A0.00
Invictus MD Strategies logo
IVITF
Invictus MD Strategies
0.6$0.04flat$0.00N/A0.00
Isodiol International logo
ISOLF
Isodiol International
0.4$0.05flat$0.00N/A0.00Gap Down
Khiron Life Sciences logo
KHRNF
Khiron Life Sciences
1.4$0.43flat$0.00N/A0.00
KHTRF
Knight Therapeutics
1.2$4.20flat$0.00N/A0.00
Marijuana Company of America logo
MCOA
Marijuana Company of America
0.5$0.01flat$0.00N/A0.00Gap Up
Medical Marijuana logo
MJNA
Medical Marijuana
0.6$0.05flat$0.00N/A0.00
MediPharm Labs logo
MEDIF
MediPharm Labs
1.2$0.40flat$0.00N/A0.00
MedMen Enterprises logo
MMNFF
MedMen Enterprises
0.8$0.35flat$0.00N/A0.00Gap Down
MERCK Kommanditgesellschaft auf Aktien logo
MKKGY
MERCK Kommanditgesellschaft auf Aktien
0.5$34.83flat$0.00N/A0.00
MJardin Group logo
MJARF
MJardin Group
0.9$0.08flat$0.00N/A0.00Gap Up
MYHI
Mountain High Acquisitions
0.5$0.03flat$0.00N/A0.00News Coverage
Gap Up
PHCEF
Pharmacielo
0.7$1.44flat$0.00N/A0.00
Plus Products logo
PLPRF
Plus Products
1.1$0.55flat$0.00N/A0.00
Premier Biomedical logo
BIEI
Premier Biomedical
0.5$0.00flat$0.00N/A0.00
PCYN
Procyon
0.4$0.70flat$0.00N/A0.00
Pure Global Cannabis logo
PRCNF
Pure Global Cannabis
0.7$0.01flat$0.00N/A0.00Gap Up
SANP
Santo Mining
0.5$0.01flat$0.00N/A0.00Gap Down
Shionogi & Co., Ltd. logo
SGIOY
Shionogi & Co., Ltd.
0.5$13.18flat$0.00N/A0.00
DNPUF
Sumitomo Dainippon Pharma
0.5$17.40flat$0.00N/A0.00
TerrAscend logo
TRSSF
TerrAscend
1.7$9.80flat$0.00N/A0.00
The Flowr logo
FLWPF
The Flowr
1.5$0.25flat$0.00N/A0.00
The Supreme Cannabis logo
SPRWF
The Supreme Cannabis
1.0$0.31flat$0.00N/A0.00Analyst Downgrade
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.